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ABSTRACT
Opioid abuse, leading to addiction and related deaths, has created a chronic epidemic
in the United States for the past 30 years. This crisis has sprung from reliance on the
prescription of opioid analgesics as the primary method for the management of pain in
the 1990’s. At that time, these drugs, specifically Purdue Pharma’s OxyContin, were
marketed as non-addictive. Due to this systemic minimization of the addictive proper-
ties of opioid analgesics, as prescription rates increased, opioid-related mortality rates
climbed. This epidemic continues to be pervasive, as opioid-related overdose resulted in
47,600 deaths in 2017. In addition to the opioid epidemic, there is mounting evidence of a
psychostimulant addiction crisis, with psychostimulant-related overdose deaths increasing
37% from 2016 to 2017. It has been shown that there is potential for the treatment of
psychostimulant and opioid addiction by antagonizing the kappa opioid receptor (KOR).
The KOR is one of three opioid receptors involved in antinociception and thus plays a role
in opioid addiction. Opioid analgesics acting on these G protein-coupled receptors lead
to an agonistic effect. Selectivity for the KOR is of interest because it also plays a role in
behavioral processes that contribute to addiction cycles, such as anxiety and depression.
Antagonizing the KOR decreases symptoms of these stress states and leads to the reduc-
tion of drug reinstatement. Salvinorin A, a naturally-occurring hallucinogenic compound,
is known to be a selective KOR agonist. Modifications of the structure of salvinorin A
have yielded compounds found to exert antagonistic effects selectively upon the KOR.
These modifications changed the topology of of the ring structure in these compounds;
thus we suspect that these new ring structures help the compounds bind better to the
inactive or active state of the KOR. This study identifies critical interactions between
salvinorin-based antagonists within the KOR, achieved by coupling structure-based drug
design and computational modeling. This approach will facilitate the creation of more se-
lective compounds for antagonizing the KOR. Docking studies performed concluded that
the topology of the salvinorin scaffold determines agonistic or antagonistic functionality
on the KOR.
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Chapter 1
Introduction
1.1 The Opioid Crisis
The opioid crisis, officially a public health emergency under federal law, is a result
of various factors and thus requires a multifaceted solution. Much of the complexity of
this crisis has stemmed from the decades-long struggle to balance and standardize pain
management with prevention and mitigation of addiction.
A lack of effective chronic pain relief methods and analgesics persisted into the lat-
ter half of the 20th century.[1] Consequently, opioids, commonly morphine, were the only
options available. Heroin, a street drug, is derived from morphine and acts on the same
receptors.[1],[2] The connection between heroin and morphine led to a rapid decrease in the
number of opioid prescriptions. There was a movement of ‘opiophobia’ throughout the
country, a panicked response that the prescription of opioids would lead to addiction.[1],[3]
The resulting reduction of analgesic prescriptions, along with a lack of systemic regula-
tion, led to mismanagement of pain, whether chronic, cancer-related, or post-operative in
nature.[1],[4] American physicians asserted that there was a state of under-treatment of pain
throughout the US, calling the drastic reduction of opioid prescriptions into question.[4]
Typically, prescription of opioids had been exclusively reserved for malignant cancer-
related pain. To combat the general lack of quality care for pain, it was suggested that
the prescription of opioids be expanded to include chronic pain states.[1],[5]
In the 1990s, prescription opioid pain relievers were marketed as non-addictive. Two
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influential yet scientifically inconclusive papers contributed to this claim.[3][6] One of these
citations is merely a letter, which anecdotally states that opioids for pain management
are not associated with addiction.[3] Therefore, there was a significant dearth of safety
tests and demonstrable outcomes. More research was necessary in order to fully consider
the complexity of human pain states, including physiological, psychological, and social
conditions, which affect the human brain and its perception of pain.[7],[1]
Despite the reality of minimal thorough scientific research on the effects of opioid
analgesics for the treatment of chronic pain, including reliable data in terms of its addictive
properties, opioids became the primary method for treating chronic and cancer-related
pain in the U.S. in the 1990s. Coupled with the efforts of physicians and programs like
the American Pain Society’s campaign for “pain as the fifth vital sign”, chronic pain cases
were rightly given more attention by doctors and the healthcare industry.[8]
New standards for pain management were created, with the primary modality of
chronic pain treatment being the prescription of analgesic opioids, specifically OxyCon-
tin, which had been marketed as non-addictive.[1],[9] Beneficially, the regulations allowed
for much-needed quantitative assessments for pain and thus essential data on the sub-
ject, but it also pushed for higher numbers of opioid prescriptions.[1],[10] This significant
increase in the number of opioid analgesics prescribed nationwide was a result of dual
causes. First, the Joint Commission (TJC) enstated new standards for pain relief, re-
quiring that physicians provide quantitative data on patient satisfaction levels in terms
of pain relief. Because such data is difficult to obtain given the subjective nature of pain,
physicians relied on prescribing opioid analgesics to boost patient satisfaction, guarantee-
ing continued federal healthcare aid.[1] Second, Purdue Pharma pressured physicians to
prescribe their opioid analgesic, often going to extremes of dubious legality. Their drug,
OxyContin was marketed as a non-addictive, humane method to relieve pain in a safe way.
Physicians feared legal consequences and being viewed as inhumane if they did not pre-
scribe these drugs.[1],[11] Ultimately, Purdue Pharma was charged for misrepresentation of
OxyContin, which by 2004 had become the leading drug of abuse after millions of dollars
spent on convincing healthcare workers of its efficacy and safety.[12] Such manipulations
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of doctors for the sale of unsafe drugs was unprecedented, and the company announced
it would pay $10 billion to settle the 2,000 lawsuits filed against it related to the opioid
crisis in 2019.[13] Due to these factors, the use of opioid analgesics escalated throughout
the 2000s before Purdue Pharma’s practices came to light.[12]
Figure 1.1: Opioid prescriptions in the U.S. from 2006 to 2018.
Adapted from the Center for Disease Control and Prevention.[14]
Though this new attitude toward prescription of opioids for pain relief afforded more
effective pain control for the patient, the adverse effects of the surplus of opioid use quickly
became apparent. Examples of these adverse effects include an increased number of
incidents of oversedation, addiction, hyperalgesia, disabilities, endocrine and psychological
co-morbidities, and mortality as a result of opioid use.[1] According to the Centers for
Disease Control and Prevention (CDC), there was a trend of quadrupling incidence of
drug poisoning deaths due to opioid analgesics from 1999 to 2012.[15]
Even given the escalating rate of addiction due to prescription opioids, physicians,
especially surgeons, continue to prescribe them in high volume, with 240 million prescrip-
tions in 2015.[16] This equates to nearly one prescription per adult in the U.S., but often
the medication is simply unnecessary. While some doctors practice judicious prescribing
procedures, many do not. Therefore, over-prescription of opioid analgesics is a key area
for improvement needed to adequately address the opioid crisis in this country. Currently,
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the most popular opioid analgesic prescribed is oxycodone.[16]
New forms of opioids have caused surges in opioid addiction and related deaths in
the U.S. The first spike in the 1990s, was due to the previously discussed over-prescribing
practices of addictive opioid analgesics. In 2010, a new spike in opioid-related deaths
was due to the rise of heroin, followed by another spike in 2013, corresponding with
the increased use of synthetic opioids like fentanyl and tramadol.[17],[18],[19],[20] Heroin is
an illegal opioid made from morphine. Synthetic opioids mimic the effects of naturally
occurring opioids like heroin and codeine but do so in much lower doses. For example,
fentanyl is 50 times more potent than heroin and 100 times more potent than morphine.[20]
Thus, it is easier to overdose on synthetic opioids, and more than 28,000 deaths in the U.S.
were a result of synthetic opioid use in 2017.[20] Opioids in any of these forms were the cause
of 47,600 deaths in 2017, six times higher than in 1999.[17] These distinctions in types of
opioid use, which caused each surge in overdose rates, are essential in identifying potential
methods for prevention and effective response to this evolving epidemic. Importantly, in
2013, 80% of heroin users confessed that they used prescription opioids before beginning
to use heroin.[21]
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Figure 1.2: Mortality rates of overdoses involving opioids, 2000 - 2017.
Adapted from the Center for Disease Control and Prevention.[20]
The condition in which the misuse of opioids leads to clinically significant impairment
and distress is defined as opioid use disorder (OUD) in the Diagnostic and Statistical Man-
ual of Mental Disorders (DSM) V.[22] Current treatments for OUD have significant issues,
such as high discontinuation rates and side effects.[23] In response to the public health
crisis of opioid misuse and opioid use disorder (OUD), the FDA is encouraging the de-
velopment of abuse-deterrent formulations (ADFs) of opioid analgesics[24] and alternative
modalities for pain management.[1] Additionally, access to medications that treat opioid
dependence, such as buprenorphine and naltrexone, has been facilitated and expanded for
increasing numbers of patients by programs such as the Drug Addiction Treatment Act
of 2000 (DATA 2000).[1]
1.2 Cocaine and Methamphetamine
The drug category of psychostimulants includes prescription psychostimulants and
illegal drugs like methamphetamine and cocaine. All of these drugs hold the potential
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for abuse and addiction. Psychostimulants increase monoamines in the brain. Specifi-
cally, methamphetamines and cocaine induce the rapid release of the neurotransmitter
dopamine in areas of the brain related to reward pathways, creating a euphoric sensation
and reinforcing drug-taking behavior patterns.[25][26] The effects of methamphetamines are
felt by the user very quickly after taking the drug, but they wear off quickly as well. These
effects can often lead to a cycle of taking repeated doses.[25] Cocaine produces a dopamine
flood, which lingers in the neuronal axes. These cells adapt to the amount of dopamine
present, decreasing their sensitivity to it. This creates a blockage in cell communication,
a state in which cocaine must be taken more frequently or in higher doses to obtain the
same high.[26]
Psychostimulants are a rapidly growing concern for public health officials. Rates for
cocaine overdose deaths have been climbing since 2012, with the most significant increase
between 2016 and 2017 claiming 14,000 lives, a 34% rise.[27] The rates of overdose deaths
due to psychostimulant drugs, not including cocaine, have been rising since 2010. The
largest increase in this category was again from 2016 to 2017, with a 37% increase, equating
to 10,000 deaths.[27] Although opioids have been and will continue to be the focus of the
drug crisis in the U.S., there is mounting evidence of a psychostimulant crisis as well.
Currently, there are no FDA-approved methods for treating psychostimulant addiction,
and behavioral therapy is the only approach used.
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Figure 1.3: Psychostimulant overdoses in the U.S., 1999 - 2018.
Adapted from the Center for Disease Control and Prevention.[28]
1.3 Opioid Addiction
1.3.1 Behavioral Mechanisms of Addiction
Drug addiction is defined as an uncontrolled craving for a substance and is manifested
in drug-seeking behaviors.[29] In the absence of pain, taking opioid drugs causes feelings
of pleasure, triggered by the same pathways that promote essential life functions such as
eating. This pathway is the mesolimbic reward system.[30] Signals in the ventral tegmental
area cause the release of dopamine in the nucleus accumbens.[31] Other areas of the brain
contribute to the creation of conditioned associations. These are memories that associate
feelings of pleasure with the environment and conditions in which the feeling occurred.
This feeling and the memory associated with it can entice individuals to keep using the
drug, especially when reexposed to the environment in which the conditioned association
was created. Memories and conditioned associations may even lead to more extreme drug-
seeking behaviors and, eventually, addiction due to cravings. The feeling of pleasure is
one of the initial factors which lead to the progression of drug abuse and addiction, but
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soon tolerance and dependence become the stronger motivational forces.[30][32]
Opioid dependence occurs when the brain no longer functions normally without the
presence of exogenous opioid. The long-term usage of opioids leads to dependence, which
is achieved once a person experiences symptoms of withdrawal when there is no exogenous
opioid in their system.[33] Opioid dependence and withdrawal occur due to changes in the
locus ceruleus, which is at the base of the brain and produces noradrenaline.[29] This
neurotransmitter stimulates wakefulness, breathing, and blood pressure. Upon opioid
binding to MORs in the locus ceruleus, noradrenaline release is suppressed. Diminished
levels of noradrenaline induce a state of drowsiness, slowed breathing, and lowered blood
pressure, typically symptoms desired by individuals with OUD.[29]
Figure 1.4: Brain areas associated with opioid addiction.
Brain illustration adapted from Project Neuron.[34]
Opioid tolerance occurs when increasing doses of the opioid are required to achieve
the same cellular response and experience of pleasure. This effect occurs by the desensiti-
zation of neurons and has been linked to the internalization of opioid receptors.[7] Opioid
tolerance can be characterized by a rightward shift in the dose-response curve of opioids
in tolerant subjects due to pharmacokinetic, pharmacodynamic, or conditioning mech-
anisms (Figure 1.5).[29] Opioid tolerance occurs because opioid-dependent neurons have
increased activity levels, thus increasing the amount of noradrenaline released. Without
opioids present, the high activity of these neurons produces the jittery, anxious symptoms
often associated with withdrawal.[30] Upon exposure to opioids, the depressive symptoms
are lessened, leading to a normal feeling. Withdrawal symptoms can only occur once a
patient has developed opioid dependence.[30]
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Figure 1.5: Effects of opioid tolerance on dose-response curve.
The dose-response curve for the opioid action obtained following analgesic opioid treatment
with morphine shows a right-ward shift, and there is an increase in the medium effective dose
(ED50) value. Adapted from Pain Research and Management.
[35]
Once an individual is dependent upon opioids, a defining factor that keeps them
chronically using the drug is withdrawal, symptoms of which begin within 24 hours of
the cessation of use in most cases.[29] Withdrawal symptoms last for up to 10 days, de-
creasing in severity over time. Symptoms include cramps, diarrhea, rhinorrhea, sweating,
elevated heart rate, and increased blood pressure, irritability, dysphoria, hyperalgesia,
and insomnia.[29] The avoidance of this withdrawal syndrome perpetuates the addiction
cycle, increasing the degrees of tolerance and dependence.
1.3.2 Molecular Mechanisms of Addiction
When a ligand binds to an opioid receptor, a conformational change in the trans-
membrane protein allows for G proteins to couple to the receptor intracellularly. These
G proteins are heterotrimeric, with Gα and Gβγ subunits. Upon coupling to the C-
terminus of the opioid receptor, the Gβγ subunit dissociates from the Gα subunit as GDP
is phosphorylated to GTP at the Gα subunit.
[36] The Gα subunit inhibits adenylyl cyclases
and cAMP production, while Gβγ subunits interact with transmembrane ion channels.
[36]
Opioid receptors attenuate the excitability of neurons by modifying pre- and postsynaptic
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calcium ion channels and adjusting the inflow of Ca2+.[37][38] All three classes of opioid
receptors may also reduce the release of pronociceptive neuropeptides, thus reducing the
sensation of pain.[39] The activation of opioid receptors also causes G protein-coupled
potassium ion channels to open, preventing the excitation of neurons and halting action
potentials.[36] The phospholipase C (PLC)/phosphokinase C (PKC) pathways can also be
activated, affecting Ca2+ channel activities. All together, the multitude of effects of the
activation of opioid receptors lead to decreased transportation of nociceptive signals and
thus a significant reduction in the sensation of pain.[36] The activation pathway of opioid
receptors is shown below in Figure 1.6.
Figure 1.6: Mechanism of opioid receptor activation.
Adapted from Opioid Treatment of Chronic Nonmalignant Pain [7]
Kinases phosphorylate intracellular regions of the opioid receptors, and specifically
GPCR kinases encourage the binding of arrestin molecules. These arrestin complexes
lead to opioid receptor desensitization by the prevention of G protein coupling at the cell
membrane. Additionally, internalization of arrestin-bound opioid receptors is promoted
as another means of desensitizing the cell to opioid receptor ligands. Dephosphorylated
opioid receptors are either reprocessed back into the cell membrane, which reestablishes
normal signal transduction, or targeted by lysosomes for degradation.[7] This opioid re-
ceptor desensitization pathway is shown below in Figure 1.7.
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Figure 1.7: Mechanism of opioid receptor desensitization.
1. Arrestin-bound receptors are internalized via a clathrin-dependent pathway and are either
2. recycled to the cell surface or 3. degraded by lysosomes.[7]
1.4 Opioid Receptors
It is crucial to discuss and understand the function of opioid receptors (ORs) and
the pathways which lead to their activation. The structures of OR ligands, the agonis-
tic/antagonistic effects of these ligands, and their mechanisms for either mitigating or
enhancing addiction is crucial in finding viable treatment options for opioid and psychos-
timulant addiction and withdrawal symptoms. It is the purpose of this study to identify
and explain structure-function models of interaction between the kappa opioid receptor
and antagonists.
1.4.1 Types of Opioid Receptors
There are three classical opioid receptors: mu (MOR), delta (DOR), and kappa
(KOR). These opioid receptors are primarily expressed by central and peripheral neurons,
but immune, neuroendocrine, and ectodermal cells have also been shown to express these
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receptors.[36] Opioid receptors are transmembrane G protein-coupled receptors (GPCRs),
belonging to the subgroup of class A gamma GPCRs.[36]
Drugs which affect opioid receptors are broken up into two categories: agonists,
which activate the receptor, and antagonists, which block receptor activity. There are
known agonists and antagonists for each classical opioid receptor type. Often, agonists of
the three opioid receptors have analgesic properties, but with that often comes addictive
properties. An example of this is morphine, an analgesic and agonist of the MOR which
is known to be addictive. Fentanyl, another MOR agonist, is a synthetically more potent
analog of morphine and is extremely addictive. Antagonists of the ORs are commonly
studied as therapies to mitigate addiction and relieve withdrawal symptoms.
This study focuses on the effects of kappa opioid receptor antagonists. Not only is
the KOR involved in the sensation of pain and antinociception, but it is also involved in
behavioral processes such as depression, anxiety, and addiction.[40] This is possible due to
the KOR’s ability to relieve the physiological effects of stress. High levels of stress and
the use of drugs that act on opioid receptors, which often go hand in hand, increase the
production and release of a KOR agonist ligand, Dynorphin.[41] This increased activation
of the KOR is known to be related to depressive and addictive states.[31] It has been shown
through multiple studies that antagonism of the KOR leads to reduced drug reinstatement
due to stress states.[31],[42] Additionally, it has been found to decrease the negative symp-
toms of withdrawal such as cramping, diarrhea, and anxiety.[33] This antagonistic effect
on depressive and addictive states has also been confirmed in cases of cocaine use.[31],[43]
Due to the similarities in mechanisms of cocaine and methamphetamines, we hypothesize
that KOR antagonism will have potential for treatment of psychostimulants.
1.5 Current Kappa Opioid Receptor Antagonists
Presently, KOR antagonists that are relatively potent and selective have been identi-
fied and entered into clinical trials. Due to issues such as long half-lives and adverse side
effects, these agents are unlikely to be developed for clinical applications. Two of these
compounds, UPHIT and DIPPA, bind irreversibly to the KOR and thus can block the
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action of KOR agonists for months.[44] Interestingly, studies involving DIPPA have shown
anxiolytic results in rats, highlighting the potential of KOR antagonism for psychological
disorders like anxiety and depression.[45]
Figure 1.8: Structures of UPHIT and DIPPA.
Other known KOR antagonists like JDTic, norBNI, and GNTI have relatively high
potencies and selectivities.[44] However, they have clinically severe drawbacks, including a
long delay before exerting their effects, a period of effect of multiple weeks at even the low-
est doses, limited brain penetration, and adverse side effects.[46] JDTic especially has been
efficacious in preclinical therapeutic models for studying opioid withdrawal, stress-induced
cocaine relapse, nicotine withdrawal, depression, and anxiety.[46],[47],[48],[49],[50] Clinical tri-
als were performed evaluating JDTic for the treatment of cocaine abuse, but testing was
discontinued after adverse events, including ventricular tachycardia.[46] NorBNI and GNTI
have been found to have antidepressant-like effects in the FST (Forced Swimming Test)
which modulates stress.[47] GNTI has poor bioavailability, limiting its utility further.[51]
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Figure 1.9: Structures of naltrexone, norBNI, GNTI, and JDTic.
Adapted from BMC Pharmacology and Toxicology.[52]
Shorter-acting KOR antagonists with more rapid absorption show more clinical promise.
Currently, the shortest-acting agent is CERC-501, with a half-life of 38.5 hours.[44] This
compound has been shown to reverse the analgesic effects of KOR agonists.[46] CERC-501
shows therapeutic effects in preclinical trials of alcoholism and also shows antidepressant-
like effects in the FST, like norBNI and GNTI.[46],[53],[54] Another agent, PF-4455242, has
exhibited similar properties and effects with promise for the treatment of OUD and related
disorders. However, there has been evidence of toxicity in animal studies when taken for
over 90 days.[46],[55] The final compound in this class is AZ-MTAB, which blocks agonistic
effects on the KOR in animal models.[44],[56]
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Figure 1.10: Structure of CERC-501.
Buprenorphine is a drug currently used to treat opioid dependence as a weak par-
tial MOR agonist, KOR and DOR antagonist, and weak partial agonist for nociceptin
receptors.[57] Because it is not a selective KOR antagonist, its therapeutic effects cannot
be linked conclusively to KOR antagonism. The combination of buprenorphine with nal-
trexone, a nonselective OR antagonist, has allowed for the creation of a relatively selective
KOR antagonist.[58] This combination proves to be a potential method for the treatment
of cocaine abuse and the prevention of relapse in both cocaine and opioid-dependent
individuals.[59][60] Clinical trials on this subject begin to link the therapeutic activity of
buprenorphine with KOR antagonism.[61],[42]
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Figure 1.11: Structure of buprenorphine.
Thus, selective, short-acting KOR antagonists are needed to determine if long and
persistent action is required to yield desired therapeutic effects and to increase the viability
of KOR antagonists for preclinical studies. The agents discussed above all have persistent
effects complicating drug development due to unfavorable pharmacodynamic effects.
1.6 Salvinorin A
Salvinorin A is a naturally occurring opioid receptor agonist and is the main active
ingredient in Salvia divinorum, a hallucinogenic plant native to Mexico.[62] It is highly
potent, shows high selectivity and affinity for the KOR, and does not show affinity for
other receptors in the body,[63] but has never advanced to clinical trials due to its strong
hallucinating effects and short half-life of 16 minutes.[64] This short half-life is partially
due to the hydrolysis of the C2 ester by esterases.[65] Salvinorin A has a unique structure
(Figure 1.12). Most naturally occurring hallucinogens target the serotonin 5-HT2a recep-
tor, whereas salvinorin A is highly selective for the KOR.[63] It is different from other KOR
agonists because it lacks a basic nitrogen, so it is not ionized at cellular pH. This basic
nitrogen was thought to be necessary for binding to an opioid receptor.[66] Qualities of
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salvinorin A, such as its hallucinogenic effects and short half-life, contribute to salvinorin
A’s perception as a poor drug for treating pain. However, its high selectivity for the KOR
has made it attractive as a lead compound for drug development.
Figure 1.12: Salvinorin A Structure.
1.6.1 Salvinorin-Based Compounds
In literature, there are only six salvinorin-based compounds have shown antagonism
against any opioid receptor (1-6, Figure 1.13). All display antagonism toward the MOR,
DOR, and KOR except 5, which is an antagonist for the MOR and DOR but has par-
tial agonist activity on the KOR.[67] Each shows varied selectivity to the KOR. All other
salvinorin-based compounds thus far have only shown OR agonism. Each of these antag-
onists show a modification at C1, replacing the ketone functional group with an alcohol,
alkene, or methylene. Though these modifications appear small, they result in differential
binding to the various ORs. It is expected that the ring undergoes a change in topology
when the ketone functional group is lost. Using crystal structures of the active and in-
active states of the KOR, interactions with salvinorin-based compounds can be explored
using these known antagonists. This study hypothesizes that selective salvinorin-based
KOR antagonists can be developed using the active and inactive KOR. These antago-
nists would have short half-lives, leading to a unique opportunity to study drug abuse,
withdrawal, and short-acting KOR antagonists. Coupling structure-based drug design
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(SBDD) and computational modeling, more selective salvinorin-based KOR antagonists
can be developed while elucidating pertinent interactions in antagonistic functionality at
the KOR.
Figure 1.13: Salvinorin-based compounds 1-6.
In order to test our hypothesis that the ring topology of the salvinorin scaffold is
directly related to its agonistic or antagonistic effects on opioid receptors, we proposed
and studied three scaffolds (A-C, Figure 1.14). The use of these scaffolds in docking
procedures will aid in formulating a complete understanding of the structure-activity
relationship between salvinorin-based compounds and opioid receptors.
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Figure 1.14: Salvinorin-based scaffolds A, B, and C.
Currently, no drugs have been approved to target the KOR. This is principally due
to limited knowledge of the molecular mechanism of KOR antagonism. The goal of this
study is to define necessary interactions for KOR antagonism and novel salvinorin-based
antagonists. The elucidation of vital interactions within the KOR will help fulfill unmet
needs in understanding the mechanisms of KOR antagonism. This subject is of particular
interest because the National Institute on Drug Abuse (NIDA) listed KOR antagonists
as one of their ”top 10 most-wanted in fighting the opioid crisis”.[68] The synthesis of
these salvinorin-based compounds was carried out simultaneously in the hopes of future
in vitro and in vivo studies. Thus, this study provides a multifaceted approach involving
structure-based drug design (SBDD) and computational methods. The computational
methods utilized include docking and molecular dynamics protocols within the active and
inactive KOR receptor X-ray crystal structures. This work will help to extend knowledge
of the structure-activity relationship of salvinorin-based compounds and elucidate crucial
interactions for desired affinity and antagonism. This knowledge can help to mold future
salvinorin-based compounds for opioid receptors and help in the creation of new KOR
ligands.
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Chapter 2
Experimental
2.1 Computational Procedures
All docking protocols were performed using Maestro 19.1, a program which focuses on
the conformation energy or Glide scores associated with ligand binding. Glide scores are
related to how entropically favored an interaction is. Compounds 1-6 (Figure 1.13) were
docked with X-ray crystal structures for the active (PDB:6B73) and inactive (PDB:4DJH)
states of the KOR, obtained from the Protein Database (PDB). The proteins were then
prepared using the Protein Prep module in Maestro. Preprocessing included adding miss-
ing side chains and removing chains B and C as well as any ligands within the receptor.
Additionally, the pH of the system was adjusted to 7.4 to mimic the physiological en-
vironment. The water molecules within the binding sites were then reviewed, and any
waters not involved in binding were removed. In the case of the active KOR, there were no
waters within its binding site. In the inactive state, waters were present, so two versions
of this protein were carried forward: one with water and one without water. These three
versions of the KOR were then optimized.
In order to dock compounds to the optimized KORs, receptor grids were generated.
Receptor grids define the binding site within the receptor, focusing the computer on this
specific area of the protein. Two methods were used in generating these grids. In cases
where an exogenous ligand was co-crystallized, an atom within that ligand was selected.
A 20 A˚ box was defined around this ligand. This was the preferred method. Alternatively,
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x,y,z coordinates were provided to create the 20 A˚ receptor grid. Rotatable groups within
3 A˚ were defined and the grid was generated. The ligands, compounds 1-6 (Figure 1.13)
and scaffolds A, B, and C (Figure 1.14), were drawn, prepared, and 3-D minimized using
the LigPrep function in the Schrodinger Suite 2019. Docking was performed using the
prepared active state KOR, inactive state KOR with waters, and the inactive state KOR
without waters on the standard precision and extra precision protocol settings. The free
energies associated with the binding of the docking-preferred complex of the salvinorin-
based antagonists and scaffolds were recorded using the Prime-MMGBSA.
2.2 Experimental Procedures
In order to fulfill the SBDD and synthetic portion of this study, we plan to synthesize
compounds 1-6 in order to further demonstrate the importance of ring topology of the
salvinorin scaffold in KOR selectivity and antagonism. Much needed in-vitro testing
will be performed upon the successful synthesis of these potential KOR antagonists. At
this time, synthesis of these compounds is ongoing. Procedures in the literature for the
following synthetic schemes did not provide the same degrees of purity and had lower
yields than reported[67], so methods had to be adjusted. We additionally implemented
minor changes in the established synthetic route[67] to make the process more efficient.
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Figure 2.1: Synthetic scheme of salvinorin-based compounds.
2.2.1 Synthetic Step A: Esterification of Salvinorin B
In order to begin the synthesis of salvinorin-based compounds (SBCs) 1,3, and 5,
acetyl chloride was esterified to salvinorin B (Figure 2.2) to afford salvinorin A, whereas
to make compounds 2, 4, and 6, the appropriate acyl chloride, benzoyl chloride, was used
to afford SBC 2a. These starting materials were prepared using the following procedure:
To a solution of salvinorin B (100 mg, 2.56 x 10-4 mmol, 1 eq) and TEA (53 µL, 5.12
x 10-4 mmol) in 20 mL DCM at 0◦C was added acid chloride (5.12 x 10-4 mmol, 2 eq)
and stirred 2 hours. The DCM was evaporated to afford the final product, which was
immediately carried on to the next reaction without further purification.
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Figure 2.2: Structure of salvinorin B.
2.2.2 Synthetic Step B: Reduction of the C1 Ketone
SBC 1: To a round-bottom flask, THF (2 mL) was added to salvinorin A, (89 mg, 0.205
mmol) and the mixture was magnetically stirred at gentle reflux for 10 min. To this was
added an aqueous solution of NaBH4 (38 mg, 1 mmol in 0.3 mL) slowly. After stirring
at reflux for 10 min, a second addition of NaBH4 powder was made (1 eq, 7.6 ng, 0.205
mmol) and reflux was continued for 5 min. The reaction mixture was then placed in an
ice bath and its progress was checked by TLC. The reaction mixture was diluted with
ethyl acetate (EtOAc) (50 mL) and extracted with saturated sodium chloride (2 X 30
mL). The aqueous phases were extracted with EtOAc (2 X 15 mL) and the combined
organic phases were dried (Na2SO4) and evaporated. Purification of the crude product
was done by column chromatography (CH2Cl2 with increasing amounts of EtOAc).
SBC 2: A mixture of SBC 2a (100 mg, 0.20 mmol) and THF (8 mL) was stirred at
reflux for 5 min. An aqueous solution of NaBH4 (38 mg, 1.00 mmol in 4 mL) was added
slowly. After stirring at reflux for 10 min, a second addition of aqueous NaBH4 was made
(8 mg, 0.21 mmol in 1 mL) and continued to reflux for 5 min. The reaction mixture was
then placed in an ice bath and its progress was checked by TLC. The reaction mixture
was diluted with ethyl acetate (EtOAc) (30 mL) and extracted with saturated sodium
chloride (2 X 30 mL). The aqueous phases were extracted with EtOAc (2 X 15 mL) and
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the combined organic phases were dried (Na2SO4) and evaporated. Purification of the
crude product was done by column chromatography (Hexanes/EtOAc, 6:4).
Note: No results were yielded from the performance of these reactions. The following
table summarizes adjustments to the reaction conditions made in order to optimize the
reduction of the C1 ketone.
Figure 2.3: Summary of reaction conditions used in reducing the C1 ketone.
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Chapter 3
Results and Discussion
In order to elucidate the interactions of compounds 1-6 and salvinorin scaffolds A-
C that confer antagonistic effects on the KOR, the docking position and interactions of
salvinorin A, an agonist, were studied for means of comparison. Another study determined
that Ile316 and Gln115 are important in the binding of salvinorin A to the KOR as an
agonist.[69] Asp138 is conserved as a -NH donor and Tyr320 is highly conserved among
GCPRs. The aromatic ring and the hydroxyl group of Tyr320 are thought to have a
crucial interaction with the methyl ester group at C2 of salvinorin A, in which salvinorin
A hydrogen bonds with its hydroxyl group.[69] Tyr313 and Tyr119 play a stabilizing role
in the agonist binding conformation, although they are not directly accessible to the
salvinorin A ligand. This stabilizing effect may be due to the lack of a strong ionic
receptor-ligand interaction between the KOR and salvinorin A.
(a) Active Purple) and inactive (Green) states
overlay.
(b) Arrows highlight the marked difference of
the inactive/active state of the KOR.
Figure 3.1: Active and inactive crystal structures of the KOR
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The results of the docking study suggest that the furan ring of the core salvinorin A
structure has a different orientation within the binding pocket depending upon whether
the KOR was in its active or inactive state (Figure 3.1). The binding of the agonist
salvinorin A demonstrates orientation of the furan ring deeper into the KOR to Tyr320
in the KOR active state. The C1 carbonyl exhibits a hydrogen bonding interaction with
Gln115 (Figure 3.2). These results confirm the expected docking interactions of salvinorin
A in the KOR.[69]
(a) Orientation of salvinorin A (Light Blue)
in the active state of the KOR (purple).
(b) 2D orientation of salvinorin A within the
active state of the KOR.
Figure 3.2: salvinorin A bound to active KOR.
Next, the known KOR antagonists 1-6 were studied using the same computational
procedure. Another study showed that the removal of the C1 ketone causes a 6-fold de-
crease in agonist activity.[70] In the antagonist bound state, Tyr320 and Lys227 contribute
to intrahelical interactions.[69] Our computational study showed that the salvinorin-based
antagonists 1-5 protrude less deeply into the binding pocket with their furan rings com-
pared to salvinorin A, leading to decreased interaction with Tyr320 (Figure 3.3). This is
due to the closed-state of the inactive binding site compared to that of the active state.
The C1 α-hydroxyl hydrogen bonds with Asp138. These interactions are a result of the
change in ring topology that occur upon substitution of the C1.
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(a) Upward orientation of SBC 3 (Dark Blue)
within the inactive state (Green).
(b) 2D interaction diagram showing key
residues that interact with SBC 3 within the
inactive state of the KOR.
Figure 3.3: SBC 3 bound to inactive KOR.
The docking poses of the salvinorin-based antagonists differ accordingly with the
change from active/inactive state of the KOR, corresponding with increased space in the
active state (Figure 3.1). Thus, in the active state, salvinorin A’s furan rings extend
farther into the receptor than the antagonists (Figure 3.4). This pose puts the ligand
in a position oriented toward residues known to be critical in KOR selectivity: Val108,
Val118, Ile294, and Tyr 312.[69] In the inactive state, SBC 3 may have a hydrogen bonding
interaction with Lys227, securing the ligand in place. The other salvinorin-based scaffolds
exhibited similar binding poses to SBC 3 (Figure 3.6).
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Figure 3.4: Overlay of salvinorin A and SBC 3
Overlay of salvinorin A (Light Blue) in the active state (Purple) and SBC 3 (Dark Blue) in
the inactive state (Green).
We hypothesized that modifying the SBCs at the C3 position to optimize the num-
ber and strength of the interactions with nearby hydrogen-bond eligible residues would
increase selectivity for the KOR over the MOR and DOR. This strategy involves increas-
ing lipophilic interactions with Val 118. Unfortunately, the synthesis of these compounds
would be arduous, especially considering stereospecificity. Thus, substitutions at C10
were considered, which could provide additional hydrogen bonding and electrostatic in-
teractions with Asp138 and Tyr312 for a similar effect in increasing selectivity. This
hypothesis was confirmed computationally, yielding improved Glide scores (Figure 3.5).
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Figure 3.5: Docking results of SBCs 1-6 and scaffolds A-C
Taken together, the results of this study provide insights into the docking poses of
KOR antagonists. These antagonists have a different pose compared to that of salvinorin
A, which can be exploited by varying the ring topology of salvinorin A with substitutions.
Changing the topology of the core structure of salvinorin A thus determines whether the
compound will bind to the active or inactive state of the KOR. Upon binding to the
active state, it has been shown that the furan ring of agonists reach more deeply into the
receptor. The designed scaffolds have similar poses to the known KOR antagonists, which
are stable, as suggested by their ∆G scores (Figures 3.5 and 3.6).
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Figure 3.6: Overlay of salvinorin-based scaffolds and SBC 3.
Overlay of SBC 3, scaffold A (Orange), scaffold B (Brown), and scaffold C (Yellow) in the
KOR inactive state.
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Chapter 4
Conclusion
Our approach of coupling structure-based drug design with computational docking
methods has provided insights into the structure-function relationship between salvinorin-
based antagonists and the KOR. The antagonists studied were salvinorin-based com-
pounds 1-6 and scaffolds A-C, novel potential KOR antagonists.
According to the docking study, the topology of the tricyclic core of the salvinorin
structure plays a role in the activity of KOR antagonists. The tricyclic core undergoes
this change in topology due to the loss of the C1 ketone, changing the molecular geom-
etry at C1 from trigonal planar to tetrahedral. The reduction in the bond angle in the
hexane ring causes a shift in the topology of the entire core ring structure of salvinorin.
This finding has allowed for the design of novel salvinorin-based scaffolds to antagonize
the KOR. In order to increase selectivity for the KOR, C10 was chosen as the site of
substitution. C10 was the best candidate due to its synthetic viability, and substitutions
were proposed to increase favorable interactions with nearby residues. These scaffolds ex-
hibited antagonism on the KOR with increased selectivity according to their glide scores,
affirming the hypothesis that ring topology plays a role in the antagonistic effect on the
KOR.
Additionally, a critical residue, Lys227, was identified as key for the binding of an-
tagonists within the active state of the KOR. We believe that this hydrogen bonding
interaction acts as an anchor holding the ligand in place. Thus, this study successfully
identified pertinent interactions for the antagonism of the KOR.
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The synthetic portion of this study is still in progress. Upon its successful completion,
we plan on obtaining in vitro, specifically IC50 analysis, and in vivo testing for these
compounds to clarify the action and binding of these salvinorin-based agents with opioid
receptors.
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